cladribine has been researched along with Dysmyelopoietic Syndromes in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Huang, W; Jin, J; Li, L; Li, M; Li, Y; Mao, X; Meng, F; Peng, Y; Tong, X; Xu, B; Zhang, D | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Hayase, T; Ito, T; Kawahara, Y; Morimoto, A; Oh, Y | 1 |
| Kishimoto, K; Kobayashi, K; Kobayashi, R; Nagashima, T; Nakanishi, M; Sano, H; Suzuki, D; Yasuda, K | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| Fathi, AT; Hasserjian, R; Sadrzadeh, H | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Fijnheer, R; Gerrits, WB; Kluin-Nelemans, HC; Oldhoff, JM; Pasmans, SG; Van 't Wout, JW; van Dobbenburgh, OA; Van Doormaal, JJ; Verhoef, G | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Höfler, G; Jäger, G; Linkesch, W; Neumeister, P | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Chou, T; Kasai, M; Kobayashi, Y; Matsuno, Y; Miura, I; Mori, S; Morishima, Y; Murayama, T; Nakamura, S; Ogura, M; Ohashi, Y; Sugai, S; Tobinai, K; Uike, N | 1 |
| Kroft, SH; Peterson, LC; Shaw, JM; Tallman, MS; Thangavelu, M | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Betticher, DC; Cabrol, C; Laurencet, FM; Zulian, GB | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Hagemeijer, A; Louviaux, I; Michaux, JL; Michaux, L; Scheiff, JM; Straetmans, N; Van Den Neste, E | 1 |
| Behm, FG; Blakley, RL; Crews, KR; Head, DR; Hurwitz, CA; Krance, RA; Mahmoud, H; Raimondi, SC; Ribeiro, RC; Roberts, WM; Srivastava, DK; Tong, X | 1 |
| Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
3 review(s) available for cladribine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
8 trial(s) available for cladribine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Cladribine therapy for systemic mastocytosis.
Topics: Adult; Aged; Antimetabolites; Biomarkers; Cladribine; Drug Eruptions; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Topics: Adult; Aged; Cladribine; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cladribine; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Staphylococcal Infections; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2002 |
11 other study(ies) available for cladribine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Chronic Disease; Cladribine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies | 2023 |
Cladribine-related myelodysplastic syndrome in Langerhans cell histiocytosis.
Topics: Antineoplastic Agents; Cladribine; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Myelodysplastic Syndromes | 2019 |
Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cladribine; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant; Magnetic Resonance Imaging; Male; Myelodysplastic Syndromes; Remission, Spontaneous | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine | 2013 |
Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Cladribine; Gastrointestinal Neoplasms; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes | 2004 |
Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 7; Cladribine; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 1997 |
Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy.
Topics: Adult; Antineoplastic Agents; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 8; Cladribine; Humans; Lymphoma; Male; Myelodysplastic Syndromes; Trisomy | 1997 |
Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine.
Topics: Adult; Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cladribine; Female; Humans; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 1999 |